ClinicalTrials.gg
RecruitingNCT04895384Updated Jul 27, 2023

El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)

An observational study in AKI, Neurocognitive Disorders and Atrial Fibrillation, sponsored by National University Hospital, Singapore. Recruiting at 2 sites in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by National University Hospital, Singapore · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
21 Years to 80 Years
Sex
All
01

Study summary

The study aims to develop a novel perioperative noninvasive delivery of oxygen (DO2) and hemodynamic index in the prediction of postoperative outcomes including post-operative acute kidney injury (POAKI), perioperative neurological cognitive disorders (PONCD) and post-operative atrial fibrillation (POAF).

Our study also aims to study the effect of DO2 and hemodynamic parameters (measured noninvasively) on the development of PONCD, POAF and POAKI in cardiac surgical patients. We aim to develop a novel DO2 index and hemodynamic index predictive of PONCD, POAF and POAKI.

The secondary aim would be to develop real-time machine learning aided algorithms in the analysis of noninvasive continuous hemodynamic and DO2 data, to predict and guide perioperative treatment of POCND, POAF and POAKI in the perioperative setting.

Read the detailed description

Postoperative acute kidney injury, AF and neurocognitive disorders (POAKI, POAF and PONCD) are common complications post cardiac surgery. Postoperative neurocognitive disorders occur in up to 73% of cardiac surgical patients, while our previous studies have demonstrated the incidence of POAF and POAKI to be 14.7% and 29.9% respectively. These perioperative complications have been shown to be associated with adverse short and long term outcomes. Apart from increased hospital length of stay and mortality, their adverse effects also extend far beyond the acute perioperative period of insult. Postoperative AKI has been shown to be associated with progression to long term renal dysfunction. Postoperative atrial fibrillation was initially thought to be a benign phenomenon, however, it has been shown to be associated with increased risk of long term stroke and mortality (Hazards Ratio 1.26 and 1.2 respectively). Postoperative delirium has is also associated with accelerated cognitive decline in Alzheimer's patients, long term cognitive decline, dementia and functional decline after discharge to the community. These phenomena remain ever pertinent in the setting of high risk and aging surgical patients, and thus need to be addressed.

The need for hemodynamic optimisation and goal directed therapy remains central to current care standards in anesthesia. This highlights the need for the quantification and improvement of cardiac output and more recently, the emerging focus on perioperative oxygen delivery (DO2) in improving clinical outcomes. Oxygen delivery can be calculated based on the oxygen flux equation: DO2 = CO x (Hb x SaO2 x 1.36); this concept of optimizing systemic oxygen delivery rather than hemodynamic parameters alone has been increasingly studied in recent times. Emerging studies involving patients undergoing cardiopulmonary bypass (CPB) have demonstrated the optimization of DO2, nadir DO2 and duration below optimum DO2 to be the most specific factors of postoperative AKI . The importance of optimizing DO2 in improving clinical outcomes is also evidenced in the critical care period, where Raimundo et al recently demonstrated that patents with a mean DO2 Index of 325ml/min/m2 were at significant risk of developing AKI which progressed to chronic renal failure, as opposed to patients who maintained a mean DO2 Index of >405ml/min/m2 . The utility of optimizing DO2 in the avoidance of postoperative delirium and atrial fibrillation however remain unknown, with previous studies being retrospective, small in sample size with conflicting results.

The use of invasive hemodynamic monitoring has been used extensively in the development of perioperative goal directed therapy protocols and hemodynamic optimization. Parameters such as MAP, CI and SVV are commonplace in the operative and ICU settings, and are used to titrate fluid, vasopressor and inotrope use. However, a delicate balance between pressure (CI, MAP) and flow (SVRI) exists in systemic organ perfusion, which may be translated into clinical outcomes such as POAF, POAKI and PONCD. Separate studies have demonstrated variations in vascular resistance to be associated with increased risk of postoperative delirium and AKI, despite the maintenance of high MAP levels. These studies indicate the possible inadequacy of MAP as the sole marker of systemic organ perfusion, and the need for further hemodynamic parameters to be studied. Our study would be the first to investigate the interplay between these SVV, SVRI, CI and MAP using non-invasive hemodynamic monitoring techniques.

In the past, this monitoring of continuous hemodynamics required invasive lines, while the continuous monitoring of DO2 was previously impossible. The use of invasive lines has been associated with multiple complications including infection, thrombosis and vascular aneurysms, while continuous DO2 monitoring would involve continuous point of care testing of hemoglobin which is impractical. Therefore, the risk benefit ratio of placing invasive lines remains controversial particularly in the routine well patient who however remains at risk of perioperative complications.

The advent of new technology has allowed for the real-time noninvasive continuous individual measurement of hemodynamics and oxygen delivery. We propose the integration of 2 new devices so as to provide the continuous noninvasive monitoring of hemodynamic data and real-time noninvasive hemoglobin and oxygen saturation - the combination of which would enable us to calculate real time systemic oxygen delivery. Continuous noninvasive hemodynamic data (the Edwards Clearsight) is based on oscillonometry and the Penaz technique which has been historically established and used in clinical practice. Continuous noninvasive hemoglobin and oxygen saturation monitoring (the Masimo SET) has been validated, and is based on established principles of spectrophotometry, oximetry and the beer lambert's law . With technological improvements over the years, these noninvasive devices have been individually evaluated against clinical gold standards in multiple studies and found to be clinically applicable in predicting perioperative hemoglobin and hemodynamic trends . Therefore, we propose the novel integrated use of these two devices in deriving a real-time noninvasive DO2 and hemodynamic index predictive of postoperative atrial fibrillation, AKI and cognitive dysfunction in cardiac surgical patients.

The integrated use of a noninvasive DO2 and hemodynamic index has yet to be studied in the context of POAF, POAKI and PONCD. Data obtained through our study may facilitate the development of new integrative technology, paving the way for the development of single index which can predict organ specific perfusion. This rich source of continuous noninvasive data will be used in the development of algorithms and mathematical models in machine learning. This would allow for the provision of precise goal directed therapy to moderate or high-risk surgical patients, especially beneficial to the geriatric setting. The potential reductions in POAF, PONCD and POAKI achieved through the clinical application of our study findings confer significant perioperative benefits which extend into the community health setting due to the long-term sequelae of these diseases.

02

Conditions studied

  • AKI
  • Neurocognitive Disorders
  • Atrial Fibrillation

Keywords

  • Postoperative
  • Perioperative
03

In context

Neurocognitive Disorders

275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.

This study's planned enrollment of 600 is above the median of 150 across 97 observational studies indexed under Neurocognitive Disorders.

Browse Neurocognitive Disorders studies →

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients scheduled for elective cardiac surgery and age above 21 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing elective cardiac surgery such as valve replacements or CABG
  • Age above 21 years old
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Emergency cardiac cases
  • Patients on IABP postoperatively
  • Patients who decline to participate in this study
  • Pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Surgical Cohort

    Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.

    Device: Edwards ClearSight and Masimo SET

Interventions

  • DeviceEdwards ClearSight and Masimo SET

    Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.

06

What researchers measure

Primary outcomes

  1. Evaluation of the incidence of primary outcomes of AKI, POAF and PONCD

    Collection of patient's demographics, medical records, surgical records and noninvasive hemodynamic data

    Time frame: Preoperative through to 90 days postoperatively

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Ranucci M, Johnson I, Willcox T, Baker RA, Boer C, Baumann A, Justison GA, de Somer F, Exton P, Agarwal S, Parke R, Newland RF, Haumann RG, Buchwald D, Weitzel N, Venkateswaran R, Ambrogi F, Pistuddi V. Goal-directed perfusion to reduce acute kidney injury: A randomized trial. J Thorac Cardiovasc Surg. 2018 Nov;156(5):1918-1927.e2. doi: 10.1016/j.jtcvs.2018.04.045. Epub 2018 Apr 18. PubMed 29778331 ↗
  • Groom RC. Is it Time for Goal-Directed Therapy in Perfusion. J Extra Corpor Technol. 2017 Jun;49(2):P8-P12. No abstract available. PubMed 28638164 ↗
  • Raimundo M, Crichton S, Syed Y, Martin JR, Beale R, Treacher D, Ostermann M. Low Systemic Oxygen Delivery and BP and Risk of Progression of Early AKI. Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1340-9. doi: 10.2215/CJN.02780314. Epub 2015 Jul 24. PubMed 26209157 ↗
  • Smulter N, Lingehall HC, Gustafson Y, Olofsson B, Engstrom KG, Appelblad M, Svenmarker S. Disturbances in Oxygen Balance During Cardiopulmonary Bypass: A Risk Factor for Postoperative Delirium. J Cardiothorac Vasc Anesth. 2018 Apr;32(2):684-690. doi: 10.1053/j.jvca.2017.08.035. Epub 2017 Aug 25. PubMed 29153931 ↗
  • Leenders J, Overdevest E, van Straten B, Golab H. The influence of oxygen delivery during cardiopulmonary bypass on the incidence of delirium in CABG patients; a retrospective study. Perfusion. 2018 Nov;33(8):656-662. doi: 10.1177/0267659118783104. Epub 2018 Jun 29. PubMed 29956559 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2024, 41 months after the start.

Of 53 non-industry observational studies under Neurocognitive Disorders, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 78. This study's planned 41 months is close to that.

Counting every sponsor, half of 54 studies reached it within 44 months; a quarter within 20 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 20, 2021
StartActual
Jul 27, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04895384
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Jul 27, 2021
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jul 27, 2023

Study contacts

Ming Ann Sim
Contact
ming_ann_sim@nuhs.edu.sg
6772 4200
Lian Kah Ti
Contact
anatilk@nus.edu.sg
6772 4200
Ming Ann Sim
principal investigator · National University Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion